Results 71 to 80 of about 21,696 (215)

Leukocytoclastic vasculitis due to ruxolitinib treatment: A rare adverse effect

, 2022
© 2021 John Wiley & Sons LtdWhat is known and objective: Primary myelofibrosis (PMF) is characterized by myeloid cell proliferation and prominent bone marrow fibrosis.
Sağlam, Buğra, Yıldız, Abdulkerim, Adabağ, Ayşegül, Albayrak, Murat, Reis Aras, Merih, Afacan Öztürk, Hacer Berna, Tığlıoğlu, Pınar, Tığlıoğlu, Mesut   +7 more
core   +1 more source

Ruxolitinib regulates the autophagy machinery in multiple myeloma cells

, 2020
Background: Ruxolitinib is a selective JAK1/2 inhibitor approved by the FDA for myelofibrosis in 2014 and nowadays, comprehensive investigations on the potential of the agent as a targeted therapy for haema-tological malignancies are on the rise.
Saydam, G., Bagca, B.G., Kusoglu, Alican, Kusoglu, A., Ay, N.P.O., Avci, C.B., Bagca, Bakiye G., Ay, Neslihan P. O., Saydam, Guray, Avci, Cigir B.   +9 more
core   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source

Discrepant Urinary Findings Between Dipstick Protein and Sulfosalicylic Acid Test in a Patient With Hyaline Casts: A Case Report

Journal of Clinical Laboratory Analysis, EarlyView.
In this post‐transplant patient, increased hyaline casts with negative dipstick protein but positive SSA testing occurred during evolving acute kidney injury and resolved with renal recovery. This discordant urinalysis pattern may warrant confirmatory protein testing and correlation with serial renal function in patients at high risk of AKI.
Yifei Jia, Binquan Chu, Fengjun Chen, Xiangyu Zhu, Chen Hang, Xiaoling Yu, Jinpiao Lin   +6 more
wiley   +1 more source

Safety evaluation of ruxolitinib for treating myelofibrosis

, 2014
Introduction: In 2005, the JAK2 V617F mutation was identified and found to be highly prevalent in the 'Philadephia Chromosome-negative' Myeloproliferative neoplasms (MPN).
Harrison, Claire, Galli, Sofia, McLornan, Donal   +2 more
core   +1 more source

Old disease, new twist

Journal of Hospital Medicine, EarlyView.
Abstract An 81‐year‐old man with a history of high‐grade urothelial carcinoma of the bladder and ureter on treatment with atezolizumab and tiragolumab presented to the emergency department with 5 months of malaise, generalized weakness, and fatigue and 2 weeks of subjective fevers. One month prior to presentation, he received an empiric 9‐day course of
Hadi Roudsari, Gurpreet Dhaliwal, Anand D. Jagannath, Alan H. Baik, Sam Brondfield   +4 more
wiley   +1 more source

Endoscopic findings in patients with Shwachman–Diamond syndrome: A report from the North American Shwachman–Diamond syndrome registry

JPGN Reports, EarlyView.
Abstract Objectives Shwachman–Diamond syndrome (SDS) is an inherited bone marrow failure disorder, and its endoscopic phenotype is poorly defined. We sought to characterize endoscopic findings in patients with genetically confirmed SDS. Methods Retrospective registry study of 45 patients with biallelic Shwachman–Bodian–Diamond syndrome mutations and ...
Elizabeth Korn, Jane Koo, Diana Schwarz, Meghan Haney, Juan Putra, Jaeson Kim, Leah Cheng, Sarah Steltz, Lois Schwarz, Sara Loveless, Richard Cooper, Claire Dusa, Kasiani C. Myers, Akiko Shimamura, Andrew Wehrman, Amit S. Grover   +15 more
wiley   +1 more source

Ruxolitinib: a targeted treatment option for patients with polycythemia vera

, 2016
Kris Vaddi,1 Srdan Verstovsek,2 Jean-Jacques Kiladjian3 1Drug Discovery, Incyte Corporation, Wilmington, DE, 2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Clinical Investigations Center, Hôpital ...
Kiladjian JJ, Vaddi K, Verstovsek S
core  

Ruxolitinib induces autophagy in chronic myeloid leukemia cells

, 2016
Ruxolitinib is the first agent used in myelofibrosis treatment with its potent JAK2 inhibitory effect. In this novel study, we aimed to discover the anti-leukemic effect of ruxolitinib in K-562 human chronic myeloid leukemia cell line compared to NCI-BL ...
Mutlu, Zeynep, Ozalp, Ozgun, Kurt, Cansu Caliskan, Avci, Cigir Biray, BİRAY AVCI, ÇIĞIR, Gunduz, Cumhur, Saydam, Güray, Bagca, Bakiye Goker   +7 more
core   +1 more source

LC‐OCT Features in Vitiligo: A Preliminary Report

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Vitiligo is a chronic depigmenting disorder characterized by the selective loss of melanocytes, leading to the progressive development of hypopigmented macules and patches. Line‐field confocal optical coherence tomography (LC‐OCT) is a novel imaging technique that combines the advantages of optical coherence tomography (OCT) and ...
Gerardo Palmisano, Daniele Omar Traini, Lorenzo Maria Pinto, Alessandra D'Amore, Mariano Suppa, Alessandro Di Stefani, Ketty Peris   +6 more
wiley   +1 more source